Common Diuretic Pauses Atherosclerosis in CKD, T2D
(MedPage Today) -- AUSTIN, Texas -- The diuretic spironolactone stopped the progression of atherosclerosis in people with type 2 diabetes and chronic kidney disease (CKD), according to the MAGMA trial.
Among 79 patients with stages 3 to 4 CKD...
Source: MedPage Today Nephrology - Category: Urology & Nephrology Source Type: news
More News: Chronic Kidney Disease | Diabetes | Diabetes Type 2 | Endocrinology | Spironolactone | Urology & Nephrology